Identification of Riluzole derivatives as novel calmodulin inhibitors with neuroprotective activity by a joint synthesis, biosensor, and computational guided strategy

• Published in: Biomedicine & pharmacotherapy Vol. 174; p. 116602
• Main Authors: Baltasar-Marchueta, Maider, Llona, Leire, M-Alicante, Sara, Barbolla, Iratxe, Ibarluzea, Markel Garcia, Ramis, Rafael, Salomon, Ane Miren, Fundora, Brenda, Araujo, Ariane, Muguruza-Montero, Arantza, Nuñez, Eider, Pérez-Olea, Scarlett, Villanueva, Christian, Leonardo, Aritz, Arrasate, Sonia, Sotomayor, Nuria, Villarroel, Alvaro, Bergara, Aitor, Lete, Esther, González-Díaz, Humberto
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-05-2024; Elsevier
• Subjects: Animals; Biological assays; Biosensing Techniques - methods; Calmodulin; Calmodulin - antagonists & inhibitors; Calmodulin - metabolism; Fluorescence Resonance Energy Transfer; Humans; Machine Learning; Molecular docking; Molecular Docking Simulation; Neurodegenerative diseases; Neuroprotective Agents - chemical synthesis; Neuroprotective Agents - chemistry; Neuroprotective Agents - pharmacology; Riluzole - chemical synthesis; Riluzole - chemistry; Riluzole - pharmacology; Riluzole derivatives synthesis; Neurodegenerative diseases; Riluzole derivatives synthesis; Biological assays; Machine Learning; Calmodulin; Molecular docking
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.116602

The development of new molecules for the treatment of calmodulin related cardiovascular or neurodegenerative diseases is an interesting goal. In this work, we introduce a novel strategy with four main steps: (1) chemical synthesis of target molecules, (2) Förster Resonance Energy Transfer (FRET) biosensor development and in vitro biological assay of new derivatives, (3) Cheminformatics models development and in vivo activity prediction, and (4) Docking studies. This strategy is illustrated with a case study. Firstly, a series of 4-substituted Riluzole derivatives 1–3 were synthetized through a strategy that involves the construction of the 4-bromoriluzole framework and its further functionalization via palladium catalysis or organolithium chemistry. Next, a FRET biosensor for monitoring Ca2+-dependent CaM-ligands interactions has been developed and used for the in vitro assay of Riluzole derivatives. In particular, the best inhibition (80%) was observed for 4-methoxyphenylriluzole 2b. Besides, we trained and validated a new Networks Invariant, Information Fusion, Perturbation Theory, and Machine Learning (NIFPTML) model for predicting probability profiles of in vivo biological activity parameters in different regions of the brain. Next, we used this model to predict the in vivo activity of the compounds experimentally studied in vitro. Last, docking study conducted on Riluzole and its derivatives has provided valuable insights into their binding conformations with the target protein, involving calmodulin and the SK4 channel. This new combined strategy may be useful to reduce assay costs (animals, materials, time, and human resources) in the drug discovery process of calmodulin inhibitors.
[Display omitted]
•Synthesis, biosensors, cheminformatics, and docking strategy for drug discovery.•Chemical synthesis procedure for Riluzole derivatives from 4-bromoriluzole.•FRET biosensor for Ca2+-dependent CaM-ligands interactions monitoring for drugs.•Predictive model for multiple biological activity parameters in different brain regions.•Docking study of CaM-Riluzole derivatives interaction.